Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Degarelix
Drug ID BADD_D00599
Description Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH) which ultimately causes testosterone suppression. Reduction in testosterone is important in treating men with advanced prostate cancer. Chemically, it is a synthetic linear decapeptide amide with seven unnatural amino acids, five of which are D-amino acids. FDA approved on December 24, 2008.
Indications and Usage Degaralix is used for the management of advanced prostate cancer.
Marketing Status Prescription
ATC Code L02BX02
DrugBank ID DB06699
KEGG ID D08901
MeSH ID C431566
PubChem ID 16136245
TTD Drug ID D0Y7KH
NDC Product Code 55566-8303; 59651-477; 55566-8403
Synonyms acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide | uglypeptide1 | Ac-2Nal-4Cpa-3Pal-Ser-4Aph(hydroorotyl)-4Aph(carbamoyl)-Leu-ILys-pro-Ala-NH2 | Firmagon | degarelix | degarelix acetate | Gonax | FE 200486 | FE200486 | FE-200486
Chemical Information
Molecular Formula C82H103ClN18O16
CAS Registry Number 214766-78-6
SMILES CC(C)CC(C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(=O)N)NC(=O)C(CC2=CC=C(C=C2)NC (=O)N)NC(=O)C(CC3=CC=C(C=C3)NC(=O)C4CC(=O)NC(=O)N4)NC(=O)C(CO)NC(=O)C(CC5=CN=CC= C5)NC(=O)C(CC6=CC=C(C=C6)Cl)NC(=O)C(CC7=CC8=CC=CC=C8C=C7)NC(=O)C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Fatigue08.01.01.002--
Febrile neutropenia08.05.02.004; 01.02.03.002--
Feeling abnormal08.01.09.014--Not Available
Gamma-glutamyltransferase increased13.03.01.011--
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal pain07.01.05.005--
Gynaecomastia21.05.04.003; 05.05.02.003--
Headache17.14.01.001--
Hyperglycaemia14.06.02.002; 05.06.02.002--
Hyperhidrosis08.01.03.028; 23.02.03.004--
Hypersensitivity10.01.03.003--
Hypertension24.08.02.001--
Hypoaesthesia17.02.06.023--Not Available
Hypotension24.06.03.002--
Immune system disorder10.02.01.001--Not Available
Incontinence17.05.01.006; 07.01.06.011; 20.02.02.004--Not Available
Influenza like illness08.01.03.010--
Injection site reaction08.02.03.014; 12.07.03.015--
Insomnia19.02.01.002; 17.15.03.002--
Joint swelling15.01.02.004--Not Available
Libido decreased21.03.02.005; 19.08.03.001--
Malaise08.01.01.003--
Menopausal symptoms21.02.02.002--Not Available
Mental disability26.01.01.001--Not Available
Micturition urgency20.02.02.006--
Muscle spasms15.05.03.004--
Muscular weakness17.05.03.005; 15.05.06.001--
Musculoskeletal pain15.03.04.007--
Myocardial infarction24.04.04.009; 02.02.02.007--
Nausea07.01.07.001--
The 2th Page    First    Pre   2 3 4    Next   Last    Total 4 Pages